Emergency planned re-infusion therapy and hospitalisation for community-acquired pneumonia: a retrospective case-control study

被引:0
|
作者
Chen, Sheng-Xian [1 ]
Yang, Zhi-Kai [1 ]
Lin, Lin [2 ]
Liao, Hou-Zhen [1 ]
Xiang, Xiao-Ting [1 ]
Liu, Di [1 ]
Huang, Jian-Shan [1 ]
机构
[1] Xiamen Chang Gung Hosp, Dept Emergency Clin, 123 Xiafei Rd, Xiamen, Fujian, Peoples R China
[2] Xiamen Chang Gung Hosp, Dept Gen Med, Xiamen, Peoples R China
关键词
LOW-RISK PATIENTS; LEVOFLOXACIN; GUIDELINES; MANAGEMENT; SEVERITY; ADULTS;
D O I
10.7189/jogh.15.04044
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Community-acquired pneumonia (CAP) is a frequent reason for emergency department visits and leads to increased direct medical costs, particularly due to hospitalisation. This study aims to examine the differences between emergency planned re-infusion therapy and hospitalisation in patients with CAP. Methods This retrospective case-control study involved 1889 CAP patients treated at the Emergency Internal Medicine Department of Class A tertiary Hospital in China from 1 January 2020 to 31 December 2022. Patients were divided into groups receiving either emergency planned re-infusion therapy or hospitalisation. Independent sample t tests and chi 2 tests were used to compare the clinical outcomes and economic impacts between the two groups across different pneumonia severity index (PSI) classifications.<br /> Results The study enrolled 1889 CAP patients. For PSI I-II patients, the improvement rates were 99.51% in the emergency planned re-infusion therapy group and 99.69% in the hospitalisation group, showing no statistically significant difference (P> 0.05). Similarly, no significant difference was observed for PSI III patients (84.16 vs. 89.82%). However, significant differences emerged for PSI IV patients, with improvement rates of 50% in the emergency planned re-infusion therapy group and 90.59% in the hospitalisation group (P < 0.001). Statistically significant differences were also noted in treatment duration (5.13 +/- 1.65 days vs. 7.60 +/- 3.93 days, P < 0.001) and total treatment costs (1921.57 Chinese Yuan (CNY) +/- 923.16 vs. 9083.80 CNY +/- 3583.55, P<0.001) between the two groups.<br /> Conclusions Emergency planned re-infusion therapy for CAP is an effective and cost-efficient alternative that can reduce both treatment duration and costs, particularly for patients with PSI I-III. It is recommended that emergency physicians give priority to emergency re-infusion therapy for patients with PSI I-III. In addition, it is recommended that hospitals strengthen the classification and treatment training programmes for emergency department physicians to recognise the patients with PSI I-IV.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Periodontal infections and community-acquired pneumonia: a case-control study
    de Melo Neto, J. P.
    Melo, M. S. A. E.
    dos Santos-Pereira, S. A.
    Martinez, E. F.
    Okajima, L. S.
    Saba-Chujfi, E.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2013, 32 (01) : 27 - 32
  • [2] Association between community-acquired pneumonia and platelet indices: A case-control study
    Motamed, Hajar
    Bashiri, Homayoon
    Yari, Farideh
    Bozorgomid, Arezo
    Rostamian, Mosayeb
    Azarakhsh, Yosef
    Hosseini, Azam
    Lorestani, Roya Chegene
    JOURNAL OF ACUTE DISEASE, 2021, 10 (01) : 23 - 27
  • [3] Diagnosis and Therapy of Community-Acquired Pneumonia in the Emergency Department: A Retrospective Observational Study and Medical Audit
    Luthi-Corridori, Giorgia
    Roth, Andrea I.
    Boesing, Maria
    Jaun, Fabienne
    Tarr, Philip E.
    Leuppi-Taegtmeyer, Anne B.
    Leuppi, Jorg D.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [4] Risk of acute pulmonary embolism in COVID-19 pneumonia compared to community-acquired pneumonia: a retrospective case-control study
    El-Sayed, M. S.
    Jones, T. A.
    CLINICAL RADIOLOGY, 2021, 76 (07) : 549.e17 - 549.e24
  • [5] Respiratory viruses associated with community-acquired pneumonia in children: matched case-control study
    Rhedin, Samuel
    Lindstrand, Ann
    Hjelmgren, Annie
    Ryd-Rinder, Malin
    Ohrmalm, Lars
    Tolfvenstam, Thomas
    Ortqvist, Ake
    Rotzen-Ostlund, Maria
    Zweygberg-Wirgart, Benita
    Henriques-Normark, Birgitta
    Broliden, Kristina
    Naucler, Pontus
    THORAX, 2015, 70 (09) : 847 - 853
  • [6] The outcome of community-acquired pneumonia in patients with COPD, asthma and ILD - a case-control study
    Dusemund, Frank
    Chronis, Joannis
    Baty, Florent
    Albrich, Werner
    Brutsche, Martin
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [7] The contribution of viruses and bacteria to community-acquired pneumonia in vaccinated children: a case-control study
    Bhuiyan, Mejbah Uddin
    Snelling, Thomas L.
    West, Rachel
    Lang, Jurissa
    Rahman, Tasmina
    Granland, Caitlyn
    de Gier, Camilla
    Borland, Meredith L.
    Thornton, Ruth B.
    Kirkham, Lea-Ann S.
    Sikazwe, Chisha
    Martin, Andrew C.
    Richmond, Peter C.
    Smith, David W.
    Jaffe, Adam
    Blyth, Christopher C.
    THORAX, 2019, 74 (03) : 261 - 269
  • [8] Community-Acquired AKI: A Prospective Case-Control Study
    Ragnarsdottir, Telma H.
    Kristjansdottir, Margret
    Gislason, Gisli
    Sanchez-Brunete, Vicente
    Tomasdottir, Margret O.
    Samuelsson, Olafur H.
    Palsson, Runolfur
    Indridason, Olafur S.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 115 - 116
  • [9] Periodontal infections and community-acquired pneumonia: a case–control study
    J. P. de Melo Neto
    M. S. A. E. Melo
    S. A. dos Santos-Pereira
    E. F. Martinez
    L. S. Okajima
    E. Saba-Chujfi
    European Journal of Clinical Microbiology & Infectious Diseases, 2013, 32 : 27 - 32
  • [10] Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia
    Hicks, Blanaid M.
    Yin, Hui
    Bladou, Franck
    Ernst, Pierre
    Azoulay, Laurent
    THORAX, 2017, 72 (07) : 628 - 634